Publications
Dec 1, 2024
Advancing Zoo Care
Ethiqa XR provides zoo veterinarians, wildlife clinicians, and husbandry teams access to effective pain management solutions, clinical support, and collaborative opportunities that enhance animal welfare. By treating with Ethiqa XR for post-procedural pain for captive rodents, ferrets, laboratory rabbits, and non-human primates, it saves time needing to administer multiple doses to the animals since Ethiqa XR is administered once and lasts up to 72 hours.
Clinical Support & Guidance
Integrate Ethiqa XR into care protocols that require treating post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. Fidelis provides access to experts treating with Ethiqa XR in these animals which will help ensure your animal is receiving appropriate pain management.
Access to Research & Data
Receive pharmacokinetic and safety information to guide your treatment decisions and documentation.
Protocol Development Assistance
Resources are available to help you develop protocols that minimize stress, streamline care, and optimize recovery outcomes.
Collaboration & Case Sharing
Opportunities exist to share clinical findings that can contribute to zoo animal welfare.
Tools to Support Your Practice
Explore a library of publications to confidently incorporate Ethiqa XR into veterinary and husbandry programs.
Trusted Care Across Zoo & Veterinary Animal Care
Ethiqa XR is indicated for the treatment of post-procedural pain in captive rodents, ferrets, laboratory animals, and non-human primates. With up to 72 hours of relief from a single subcutaneous injection and a proven safety profile, veterinarians can provide compassionate care that supports recovery and well-being.
- Captive Rodents and Ferrets
- Non-human Primates
Reliable Pain Relief for Captive Rodents and Ferrets
Ethiqa XR is FDA-indexed for post-procedural pain in captive rodents. A single subcutaneous injection provides up to 72 hours of steady analgesia. The need for fewer injections reduces stress and supports overall welfare.
Safe Post-Procedure Pain Relief for Non-Human Primates
Ethiqa XR provides reliable, extended analgesia for a variety of non-human primates. Its proven safety and efficacy allow caretakers and veterinarians to confidently manage pain while promoting welfare across these diverse species.
Built on Safety & Reliability
Ethiqa XR is FDA-indexed for control of post-procedural pain for captive rodents, ferrets, laboratory rabbits, and non-human primates. Manufactured under cGMP regulations, it delivers the highest quality and compliance standards to support zoo and veterinary facilities for these indicated animals.
-
FDA-Indexed for Veterinary Use
Ethiqa XR is an indexed drug indicated for post-procedural pain for use across captive rodents, ferrets, laboratory rabbits, and non-human primates.
-
DEA & cGMP Standards
Manufactured, tested, and compliant with FDA regulations. Compliant with controlled substance regulations.
-
Full Transparency
Labeling for Ethiqa XR reflects the current safety and efficacy information. Publications are available on the Ethiqa XR website
FAQs
We’ve answered some of the most common questions about Ethiqa XR’s use, safety, and support.
See All FAQs
What is the NDC number for Ethiqa XR?
The NDC number is 86084-100-30.
How long is analgesia shown to last?
In the pharmacokinetic studies, therapeutic drug concentrations of Ethiqa XR were maintained for up to 72 hours post-injection in captive rodents, ferrets, laboratory rabbits, and non-human primates.
Does Ethiqa XR require refrigeration?
Ethiqa XR does not require refrigeration and should be stored at room temperature, specifically between 15° to 25°C +/- 2°C (59°F to 77°F). If Ethiqa XR has been refrigerated, it should be allowed to reach room temperature before use. Do not heat Ethiqa XR. Heating the product or not storing the product in its original container or within the specified storage conditions could cause the product to change its physical properties.
For what species is Ethiqa XR indicated?
Ethiqa XR is indicated for control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. See the Package Insert, including Boxed Warning, for additional details.
What is the return policy?
Ethiqa XR is a controlled drug substance (CIII) and is generally not returnable; however, the return policy is determined by the distributor. For additional information, please contact your distributor.
Backed by Research, Built for Better Husbandry
We’re Here to Support You
Your insights matter because animal care starts with true collaboration. Ethiqa XR is a trusted, science-backed product for the control of post-procedural pain in captive rodents, ferrets, laboratory rabbits, and non-human primates. We are here to support you every step of the way. Connect with our team, ask questions, and stay informed. Together, we’re advancing animal welfare and helping you deliver the highest quality care.
Contact Us
Real people providing dedicated support
Direct access to experienced veterinary experts
Backed by rigorous, proven research data.
ETH.LP.214.01.D.ALL.AL
Boxed Warning
Abuse Potential
ETHIQA XR contains buprenorphine, an opioid that exposes humans to risks of misuse, abuse, and addiction, which can lead to overdose and death. Use of buprenorphine may lead to physical dependence. The risk of abuse by humans should be considered when storing, administering, and disposing of ETHIQA XR. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drugs or alcohol) or mental illness (e.g., depression).
Life-Threatening Respiratory Depression
Serious, life-threatening, or fatal respiratory depression may occur with accidental exposure to or with misuse or abuse of ETHIQA XR. Monitor for respiratory depression if human exposure to buprenorphine occurs. Misuse or abuse of buprenorphine by swallowing, snorting, or injecting poses a significant risk of overdose and death.
Accidental Exposure
Because of the potential for adverse reactions associated with accidental exposure, ETHIQA XR should only be administered by veterinarians, veterinary technicians, or laboratory staff who are trained in the handling of potent opioids. Accidental exposure to ETHIQA XR, especially in children, can result in a fatal overdose of buprenorphine.
Risks From Concurrent Misuse or Abuse with Benzodiazepines or Other CNS Depressants
Concurrent misuse or abuse of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.
See HUMAN SAFETY WARNINGS for detailed information.
Important Safety Information
For Captive Rodents, Ferrets, Laboratory Rabbits, and Non-Human Primates:
Only administer Ethiqa XR® by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use in animals with pre-existing respiratory compromise.
Death has been reported when non-steroidal anti-inflammatory drugs (NSAIDs such as meloxicam and carprofen) and Ethiqa XR have been administered concomitantly in mice.
Do not house rats on wood chip-type bedding after administration of Ethiqa XR. Pica involving wood chip type bedding can be lethal.
Ethiqa XR may cause sedation, decreased blood pressure, decreased heart rate, decreased gastrointestinal mobility, and respiratory depression. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. Animals should be monitored for signs of decreased cardiovascular and respiratory function when receiving Ethiqa XR.
The safety of Ethiqa XR has not been evaluated in pregnant, lactating, neonatal, or immune-compromised animals.
For Humans:
Not for use in humans. Keep out of reach of children and pets.
Ethiqa XR contains buprenorphine, a Schedule III controlled substance with an abuse potential similar to other Schedule III opioids, which may lead to overdose and death.
Ethiqa XR should be handled appropriately to minimize the risk of misuse, abuse, addiction, and criminal diversion, including restriction of access, the use of accounting procedures, and proper disposal methods as appropriate to the laboratory setting and as required by law.
Ethiqa XR should only be handled and administered by a veterinarian, veterinarian technician, or laboratory staff trained in the handling of potent opioids. Wear protective clothing when administering Ethiqa XR to avoid direct contact with human skin, eyes, oral, or other mucus membranes which could result in absorption of buprenorphine and adverse reactions.
For more information, consult the Prescribing Information including the Boxed Warning.
SA.EthiqaXR.060.05.2024